Friday, 28 February 2020

Regeneron, Sanofi's drug shows positive effect in lung cancer study

18 May 2018 | News

Regeneron's U.S. marketing application seeking approval for cemiplimab, a PD-1 inhibitor, for cutaneous squamous cell carcinoma is currently under FDA review with an action date of October 28.

 Singapore- Regeneron Pharmaceuticals and development partner Sanofi announce positive preliminary data from a Phase 1 clinical trial assessing cemiplimab in advanced non-small cell lung cancer (NSCLC). The results will be presented at ASCO in Chicago.

The overall response rate was 29% (n=6/21), all partial, and the disease control rate (responders + those with stable cancer) was 57% (n=12/21) as of the data cutoff date. Duration of response exceeded eight months in five of the six responders.

Regeneron's U.S. marketing application seeking approval for cemiplimab, a PD-1 inhibitor, for cutaneous squamous cell carcinoma is currently under FDA review with an action date of October 28.

Sign up for the editor pick and get articles like this delivered right to your inbox.

Editors Pick
+Country Code-Phone Number(xxx-xxxxxxx)


Comments

× Your session has been expired. Please click here to Sign-in or Sign-up
   New User? Create Account